AddLife 2

Interim report 1 January – 30 September 2023

Continued strong organic growth in both business areas

"AddLife's growth plan is working well and, after a period of COVID-19 and acquisition-driven growth, we are now seeing robust organic growth. Profitability has improved and we have implemented a number of measures that are expected to support a positive profitability trend moving forward. The activities to improve cash flow have been successful and we are excited that we have completed an add-on acquisition in the quarter."

Fredrik Dalborg, President and CEO

1 JULY - 30 SEPTEMBER 2023 (3 MONTHS)

- Net sales increased by 10% to SEK 2,319 m (2,100). The COVID-19 related sales decreased to 0 m (151) and the organic growth, excluding COVID-19 related sales and exchange rate changes, was 10%.
- EBITA decreased to SEK 244 m (288), corresponding to an EBITA-margin of 10.5% (13.7). Adjusted for reversed contingent considerations, EBITA increased by 12% and amounted to SEK 227 m (203), corresponding to an EBITA margin of 9.8% (9.7).
- Financial income and costs amounted to -71 m (-41)
- Profit after tax amounted to SEK 26 m (120).
- Earnings per share amounted to SEK 0.20 (0.99).
- Cash flow from operating activities amounted to SEK 138 m (20).
- During the quarter an acquisition, Emmat Medical Ltd, was completed. The acquisition is estimated to contribute an annual net turnover of approximately SEK 28 m.

1 JANUARY - 30 SEPTEMBER 2023 (9 MONTHS)

- Net sales increased by 6% to SEK 7,141 m (6,758), whereof the acquired growth amounted to 1%. The COVID-19 related sales decreased to 0 m (696) and the organic growth excluding, COVID-19 related sales and exchange rate changes, was 10%.
- EBITA decreased by 11% to SEK 857 m (963), corresponding to an EBITA-margin of 12.0% (14.3). EBITA include reversed contingent considerations amounting to 101 m (85), adjusted for this the EBITA-margin amounts to 10.6% (13.0).
- Profit after tax amounted to SEK 233 m (421).
- Earnings per share amounted to SEK 1.90 (3.46). Earnings per share for the last 12 months amounted to SEK 2.40 (4.92).
- Cash flow from operating activities amounted to SEK 325 m (558).
- The equity ratio was 39% (38).
- Return on working capital (P/WC) amounted to 49% (61).

10 % ORGANIC GROWTH 9m 2023

10 % ORGANIC GROWTH Q3 2023

AddLife 2

	3 months ending			9 months ending			12 months ending	
SEKm	30 Sep 23	30 Sep 22	change	30 Sep 23	30 Sep 22	change	30 Sep 23	31 Dec 22
Net sales	2,319	2,100	10%	7,141	6,758	6%	9,467	9,084
EBIT	132	183	-28%	526	659	-20%	675	808
EBITA	244	288	-15%	857	963	-11%	1,115	1,221
EBITA-margin, %	10.5%	13.7%		12.0%	14.3%		11.8%	13.4%
Profit before tax	61	142	-57%	337	525	-36%	414	602
Profit for the period	26	120	-78%	233	421	-45%	295	483
Earnings per share before dilution, SEK	0.20	0.99	-80%	1.90	3.46	-45%	2.40	3.96
Earnings per share after dilution, SEK	0.20	0.98	-80%	1.90	3.45	-45%	2.40	3.95

NET SALES (SEKM)





